Kazia Therapeutics Stock Falls 18%
Kazia Therapeutics (KZIA) shares started at $0.33 on Wednesday. Their average prices are $0.38 for 50 days and $0.35 for 200 days. The stock has ranged from a low of $0.19 to a high of $1.58 over the past year.
Analyst Updates
HC Wainwright maintained a “buy” rating for Kazia Therapeutics with a target price of $2.00 as of July 12.
About Kazia Therapeutics
Kazia Therapeutics develops anti-cancer drugs, including Paxalisib, aimed at treating various brain cancers and other solid tumors.
Read More
- Five stocks we prefer over Kazia Therapeutics
- 3 REITs to Buy and Hold
- Goldman Sachs Earnings Insights
- Insider Trades Misconceptions
- AMD’s AI Momentum and Expectations
- Understanding Forex
- 2 Lithium Stocks As Potential Takeover Targets
Stay Updated on Kazia Therapeutics News – Enter your email to receive daily updates about Kazia Therapeutics and related companies from MarketBeat.com’s FREE newsletter.
`
